Fig. 4: The triple combination of venetoclax, artesunate, and cytarabine is more effective at inhibiting leukemia cell growth and inducing DNA damage. | Cell Death & Disease

Fig. 4: The triple combination of venetoclax, artesunate, and cytarabine is more effective at inhibiting leukemia cell growth and inducing DNA damage.

From: Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Fig. 4: The triple combination of venetoclax, artesunate, and cytarabine is more effective at inhibiting leukemia cell growth and inducing DNA damage.The alternative text for this image may have been generated using AI.

THP-1 cells were treated with 0.8 μM artesunate, 0.1 μM venetoclax, and 0.5 μM cytarabine alone or in combination. MOLM-13 cells were treated with 0.2 μM artesunate, 0.01 μM venetoclax, and 0.005 μM cytarabine alone or in combination. A Growth inhibition of the different combination were measured after 72 h treatment. B The number of colonies were counted and calculated as a percentage of the control after 14 days. C THP-1 cells were treated with 0.8 μM artesunate, 0.1 μM venetoclax, and 8 μM cytarabine alone or in combinations for 24 h. MOLM-13 cells were treated with 0.2 μM artesunate, 0.01 μM venetoclax, and 0.08 μM cytarabine alone or in combination for 12 h. Apoptosis induction measured based on Annexin V/PI staining. D Cell cycle assessed after PI staining by flow cytometry. Values are mean ± SD of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 compared to the control group by t-test. #P < 0.05; ##P < 0.01; ###P < 0.001 by two-way ANOVA test.

Back to article page